2.8 C
Munich
Saturday, February 4, 2023

BioXcel Therapeutics Inc (NASDAQ: BTAI) Stock Technically Breaks Out After Initiating Trial For BXCL501

BioXcel Therapeutics Inc (NASDAQ: BTAI) made a new high in yesterday’s session, and closed the day with gains of 40.35%. This followed the company’s announcement that it had started its Sub-Lingual Dexmedetomidine in Agitation Associated with Schizophrenia and Bipolar disorder study (SERENITY) program. The two-phase studies are for treating acute agitation in patients with schizophrenia and bipolar using the company’s treatment called BXCL501.  The company expects to receive data from these trials in mid-2020.

Commenting on the progress, the CEO,  Vimal  Mehta stated that, the start of SERENITY trials was a major step towards their goal of offering an effective and safe treatment for people dealing with agitation that comes with schizophrenia and bi-polar. He added that, handling agitation in people suffering from these disorders is a big challenge to all involved, including physicians and the patient’s caregivers. 

Hefurther stated that, BXCL501 was designed in a way that it is non-invasive,acts quickly, and may overcome the challenges that come with the existingstandards of care. He added that, the company believes the treatment givespatients a calming effect, without the need for excessive sedation that mighthurt the relationship that exists between the patient and the caregiver.

The company’s studies for this treatment are randomized, and double-blind. They are also placebo-controlled and will involve 750 patients aged between 18 and 75. The company intends to take in patients with schizophrenia linked agitation and that each will either receive BXCL501 or a placebo. The dosage will either be 120 mg of the treatment or 180mg of the placebo.

Themain endpoint of the trial is to cut down on acute agitation when measured bythe positive and negative syndrome scale. Its main secondary endpoint is todetermine the earliest point of agitation.

Lookingat its price action, the SERENITY studies announcement pushed a stock that wasalready in an upside trajectory higher. In the day, it traded between a low of$10.52 and a high of $14.80 before closing the day at $14.61. Volumes in theday stood at 680.2k.

About BioXcel TherapeuticsInc

BioXcelTherapeutics Inc is a biopharma company that develops new treatments in theareas of immune-oncology and neuroscience. It is based in New Haven, Connecticut.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.